newsfilter
← Latest News
GlobeNewswire·

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel